Cohance Lifesciences shares hit 20% upper circuit on appointing former Cipla CEO as Executive Chairman and Group CEO

The stock has surged 17% in the past week and nearly 43% over the month. However, on a year-to-date basis, it has declined 17%.

While the scrip hit a 52-week high of ₹1,235 on April 24, 2025, it touched a year’s low of ₹266.70 per equity share on March 9, 2026.

Umang Vohra will step into his role as the Executive Chairman of the company from May 1, 2026, and Group CEO, effective May 20, 2026, according to a regulatory filing.

Vohra will succeed Vivek Sharma, who will step down from the post of Executive Chairman due to personal reasons. However, Sharma will continue to be with Cohance as an Advisor for the next nine months and will support a smooth transition.

“Over the past few years, we have built a strong foundation for Cohance — integrating businesses, strengthening the leadership team, and establishing the platform’s identity as a science-led CDMO. I am proud of what the team has achieved and confident that the platform is well-positioned for its next chapter. I wish Umang and the entire Cohance team every success as they take the company forward,” Vivek Sharma stated.

The new CEO will lead the next phase of transformation and growth at Cohance and help build India’s leading technology-driven CDMO platform, the company added.

“The appointment of Mr. Vohra reflects a deliberate, strategic decision taken by the Board to bring in a leader whose profile is specifically suited to the demands of the company’s transformation and its next phase of growth,” the Hyderabad-based firm stated.

With a career spanning over three decades, Umang Vohra has led large, complex, global businesses through periods of strategic transformation while maintaining an “unwavering focus on customers, quality and operational excellence.”

Most recently, as CEO and Managing Director of Cipla Limited, Vohra led the company’s transformation over the last decade to build a diversified global pharmaceutical enterprise.

Having worked in and transformed two very large and respected Pharma companies in India, Vohra brings an owner-mindset and vast experience in business to the Cohance platform, the company added.

Commenting on the appointment, Umang Vohra said: “I am very excited to be joining Cohance. I believe deeply in the long-term value creation potential of this platform. Cohance’s technology offerings, depth of its R&D talent, and the quality of the leadership team already in place provide a strong foundation. I am looking forward to this entrepreneurial stint and will work closely with the current management leaders to create value for customers, employees, and shareholders alike.”

Cohance Lifesciences has a total market capitalisation of ₹16,530.73 crore as of April 27, 2026, according to data on the NSE.